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The aim of this study is to evaluate temporal trends, treatment and clinical outcomes of patients 
who present with an acute myocardial infarction (AMI) and have a current or historical 
diagnosis of cancer, according to cancer type and presence of metastases. 
Methods and Results:  
Data from 6,563,255 patients presenting with an AMI between 2004-2014 from the US 
National Inpatient Sample (NIS) database were analysed. A total of 5,966,955 had no cancer, 
186,604 had current cancer and 409,697 had a historical diagnosis of cancer. Prostate, breast, 
colon and lung cancer were the four most common types of cancer. Patients with cancer were 
older with more comorbidities. Differences in invasive treatment were noted, 43.9% received 
percutaneous coronary intervention (PCI) in patients without cancer whilst only 21.0% of 
patients with lung cancer received PCI. Lung cancer was associated with the highest in-hospital 
mortality (odds ratio (OR) 2.71 95% confidence interval (CI) 2.62,2.80), major adverse 
cardiovascular and cerebrovascular complications (OR 2.38 95% CI 2.31,2.45) and stroke (OR 
1.91 95% CI 1.80,2.02), while colon cancer was associated with highest risk of bleeding (OR 
2.82 95% CI 2.68,2.98). Irrespective of the type of cancer, presence of metastasis was 
associated with worse in-hospital outcomes, and historical cancer did not adversely impact on 
survival (OR 0.90, 95% CI 0.89,0.91).  
Conclusions 
A concomitant cancer diagnosis is associated with a conservative medical management strategy 
for AMI, and worse clinical outcomes, compared to patients without cancer. Survival and 
clinical outcomes in the context of AMI vary significantly according to the type of cancer and 
metastasis status. The management of this high-risk group is challenging and requires a multi-
disciplinary and patient-centred approach to improve their outcomes. 
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Introduction 
Cardiovascular disease and cancer together account for nearly 70% of disease-related 
mortality in developed countries.1 Advances in therapies for cancer have resulted in a decline 
in mortality, thereby increasing life expectancy in cancer survivors. A significant number of 
patients with active malignancy or a history of it will present with cardiovascular disease, that 
has been shown to be the leading cause of death in cancer survivors 2. The risk of cardiovascular 
disease varies depending on the type of cancer and therapy that the patient has been subjected 
to, ranging from two fold higher risk in testicular cancer survivors 3 to a seven fold higher risk 
in survivors of childhood malignancies 4.  Although cardiovascular disease and cancer are 
thought of as two distinct disease processes, there is considerable overlap in etiopathogenesis 
both at an epidemiologic and molecular level. Whilst shared epidemiologic risk factors such as 
age, smoking 5, diabetes 6 and obesity 7 are well known, the complex molecular mechanisms 
that are responsible for these diseases and the interplay between them remains less clearly 
understood.  
Patients with a malignancy pose several challenges when presenting with an acute 
myocardial infarction (AMI). They are often older 8-10, with more comorbidities 10, 11 and have 
more extensive coronary artery disease (CAD) 8. Their hematologic and coagulation 
abnormalities pose challenges to the use of anticoagulants, antiplatelet agents and percutaneous 
coronary intervention (PCI). There is limited evidence-based guidance in this cohort, further 
adding to the clinical dilemma. 12, 13 Patients with active malignancy have been excluded from 
randomised controlled trials that have been used to define best practice in AMI. Furthermore, 
there is omission of cancer from all contemporary risk stratification scores used to define 
ischemic and bleeding risk, despite the fact that cancer diagnosis has far greater implications 
than the comorbidities included in these scores. 14-17   
There are limited data on clinical outcomes following AMI in patients with a cancer 
diagnosis, as studies in the literature currently do not differentiate between current and prior 
cancer diagnoses, cancer type or the presence of metastases. We, therefore, sought to analyse 
the temporal trends, treatment patterns and clinical outcomes in a large contemporary cohort 
of over 6 million patients with AMI stratified by the type of cancer diagnosis and presence of 
metastasis over a 10-year period using the National Inpatient Sample (NIS) database a publicly 





Data was obtained from the US National Inpatient Sample (NIS) between 2004- 2014. The NIS 
is an all-payer database developed by the Agency for Healthcare Research and Quality 
(AHRQ), as part of the Healthcare Cost and Utilisation project (HCUP).18 The NIS database is 
made up of hospital admission data, and represents approximately 20% of US hospital 
admissions each year. Unweighted, the NIS contains information from 7 to 8 million 
admissions each year. Discharge weights are provided to give national estimates. The NIS 
contains no individual patient identifier, therefore repeat admissions in the same year or across 
multiple years are unable to be identified. Since 2012, the NIS samples discharges from all 
hospitals participating in HUCP, approximating a 20% stratified sample of all discharges from 
US community hospitals. The sampling strategy has changed over time in order to produce 
more generalizable estimates by reducing sampling bias.  Before 2012 the NIS retained all 
discharges, but only from a sample of hospitals.  
 
Study design 
The NIS was used to identify patients who were admitted to hospital with a primary 
diagnosis of AMI. Using the international classification of disease, ninth edition, clinical 
modification (ICD-9-CM) codes, primary admission with ST-segment elevated myocardial 
infarction (STEMI) was identified using codes 410.0x, 41.01x, 410.2x, 410.3x, 410.4x, 410.5x, 
410.6x, 410.8x, 410.9x and non ST-segment elevated myocardial infarction (NSTEMI) using 
410.7x. Only patients with a primary diagnosis of AMI were considered. Hospitalisations were 
excluded if the patient was under the age of 18.  
Baseline patient characteristics included patient age, sex, median household income, 
primary expected payer and hospitalization admission day (weekday/weekend). We also 
included information about the hospital to which the patient was admitted including bed size 
and teaching/location status. Additional patient comorbidities were identified from the 
diagnosis codes using ICD-9-CM codes. These included known CAD, smoking status, prior 
MI or stroke, prior PCI and prior coronary artery bypass graft (CABG), chronic obstructive 
pulmonary disease (COPD). Finally, Elixhauser comorbidities were also considered.  
For each patient who had been admitted with a primary diagnosis of AMI, patients with 
either a current cancer diagnosis or a historical diagnosis were identified. Current cancer 
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diagnoses were found using the clinical classifications software codes, with ICD-9-CM codes 
being used to identify the historical cancer diagnoses. The 30 most common types of cancer 
were in this population were considered (presented in Supplemental Table 1).  
Patient treatments and complications 
Supplemental Table 2 overviews ICD-9-CM codes used to identify patient 
characteristics, complications and procedures. Procedural ICD-9-CM codes were used to 
determine treatment received by the patient. These included coronary angiography (88.52 
88.53 88.54 88.55 88.56 37.22 37.23), percutaneous coronary intervention (00.66 36.01 36.02 
36.06 36.07 3609) or coronary artery bypass graft (36.1x 36.20 36.31 36.32 36.9x). If none 
were recorded it was assumed that the patient had been medically managed. The NIS does not 
capture pharmacological data. Other procedural characteristics that were considered include 
long-term or short-term ventricular assist device (VAD), intra-aortic balloon pump (IABP), 
and intubation or mechanical ventilation.  
Clinical Outcomes 
In-hospital clinical outcomes including mortality, major adverse cardiovascular or 
cerebrovascular events (MACCE) (a composite of all-cause mortality, cardiac complications 
and stroke), stroke and bleeding were identified. Cardiac complications included 
hemopericardium, cardiac tamponade, need for pericardiocentesis and occurrence of coronary 
dissection. Bleeding complications included gastrointestinal, retroperitoneal, intracranial, 
intracerebral haemorrhage, unspecified haemorrhage, and whether a blood transfusion was 
required. The ICD-9-CM codes used to identify the clinical outcomes are given in 
Supplemental Table 2. The length of stay on the discharge record and the total billed 
hospitalisation charge for each individual discharge were recorded. As the total billed charge 
is not representative of the hospital services cost, a charge to cost conversion ratio was used in 
order to covert the reported charges into the actual cost for the payer.  
 
Statistical analysis 
Continuous variables are expressed as median and interquartile range between 
parentheses (IQR) due to skewed nature of the data. Categorical variables are expressed using 
percentages. Where missing data were less than 10% of the covariate data, the observations 
with missing data were removed. Data was assumed to be missing at random. 
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For calculation of national estimates and correct variances, sampling weights for each 
individual discharge that were provided by the AHRQ were used. In order to ensure that the 
analysis provided an accurate national representation, weighted estimates were produced using 
the survey analysis method (svy command in Stata). Individual weights were provided for each 
record, with a hospital variable to account for clustering within hospitals. Due to the redesign 
of the NIS data and the alternative sampling strategy used before 2012, these weights needed 
to be updated from the original sampling weights for 2004-2011 in order for the analysis to be 
conducted across all included years. All analyses were conducted using Stata 14.  
Multivariable analyses were used to look at the impact of cancer diagnoses on the 
clinical outcomes. Logistic regression models were fitted to examine the association between 
current or historical cancer diagnoses and in-hospital outcomes (mortality, MACCE, stroke and 
bleeding), presented as odds ratios (OR) with corresponding 95% confidence interval (CI). In 
order to assess the impact of the cancer diagnosis, all models were adjusted for potential 
confounders. These included age, gender, median income, expected payer, elective admission, 
hospital bed size and location, diagnosis of shock, use of VAD or IABP, history of CAD, 
previous MI, previous CABG, previous stroke, previous PCI, STEMI diagnosis, treatment and 
year of hospitalisation, as well as the Elixhauser comorbidities. The models were adjusted for 
the patient, hospital and procedural characteristics listed in Table 1. Other models were fitted 
to examine the association between the following subgroups and aforementioned outcomes; 1) 
the most prevalent current cancers, 2) the presence of metastases, 3) patients with only STEMI 
diagnosis, and 4) patients admitted between 2010 and 2014. Further models were fitted to 
examine predictors of receipt of invasive management (coronary angiography, PCI and 
CABG). As a sensitivity analysis, a propensity score matching was used to calculate the 
average treatment effect, which was the difference between a cancer diagnosis or no cancer 
diagnosis.  
Results 
A total of 6,563,255 weighted records were identified with a primary diagnosis of AMI 
between 2004 and 2014 excluding records with missing information and/or patients under the 
age of 18, accounting for approximately 3% of records (Figure 1). Between 2004 and 2014 
there was a small rise in the rate of patients admitted with a primary diagnosis of AMI with a 
current diagnosis of cancer (2004 to 2014: 2.5% to 3.0%), and an even greater rise in the rate 
of patients admitted with a historical cancer diagnosis (2004 to 2014: 4.8% to 7.7%).   
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The 10 most prevalent cancer types and the percentage of records that had either a 
current or historical diagnosis of these cancers are shown in Supplemental Figure 1. The most 
common current cancer diagnosis was lung cancer followed by prostate cancer and leukaemia. 
For historical cancers the most prevalent was prostate cancer followed by breast cancer.   
1. Cancer diagnoses 
The patient characteristics of each of the considered groups (no cancer, current cancer 
and historical cancer) are shown in Table 1. The prevalence of STEMI was 29.0% in the current 
cancer group, 28.7% in the historical cancer group and 36.0% in the no cancer group. Cancer 
patients were older (median ages of 75 (67,82) years and 77 (67,84) years compared to 67 
(56,79) years). Female prevalence was highest in the historical cancer cohort (43%) and lowest 
in the current cancer group (35%). The prevalence of previous MI, PCI or CABG were similar 
across the groups. The rates of deficiency anaemia were higher in both the current and historical 
cancer diagnoses compared to the no cancer group, as were the rates of complicated diabetes 
mellitus and chronic renal failure. Patients with current cancer had a higher prevalence of 
COPD, coagulopathy, fluid and electrolyte disturbances and weight loss.  
1.1 Management strategy 
The crude rates of invasive procedures (coronary angiography, PCI and CABG) 
according to timing of cancer are presented in Figure 3. Patients with a current cancer diagnosis 
had the lowest rates of PCI and CABG, compared to those without cancer or with a history of 
cancer, and the highest rates of coronary angiography. These findings persisted in multivariate 
analysis where patients with current cancer were associated with significantly lower odds of 
all 3 procedures (OR coronary angiography: 0.54 95% CI 0.54, 0.55, PCI: 0.64 95% CI 0.63, 
0.65 and CABG: 0.44 95% CI 0.43, 0.45) compared to those without cancer. (Supplemental 
Table 3) Patients admitted to larger bed size (vs. small bed size) and urban (vs. rural) hospitals 
were more likely to undergo invasive management, as were patients admitted to US regions 
other than the Northeast.  
1.2  Clinical Outcomes 
In-hospital mortality was almost twice as high in patients with a current cancer 
diagnosis than those with historical or no cancer, (11.1% vs 5.4% and 5.7% respectively). 
(Table 3) MACCE and stroke were also significantly higher in the current cancer group, 
compared to both the historical group and the no cancer group (MACCE: 13.3% vs. 7.2% and 
7.7%, respectively, and stroke: 2.4% vs. 1.5% and 1.7%). Similar patterns were observed for 
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bleeding complications, where the current cancer group had twice the rates of bleeding than 
the historical cancer and no cancer groups (18.4% vs 9.7% and 8.8% respectively). Patients 
with a current cancer diagnosis had an increase in the odds of in-hospital mortality compared 
to those with no cancer (OR 1.68 (95% CI 1.65,1.71)). (Supplemental Table 5) In contrast, 
patients with a historical cancer diagnosis had decreased odds of mortality (OR 0.90 (95% CI 
0.89,0.91)). Patients with a current cancer diagnoses had increased odds of MACCE (OR 1.53 
(95% CI 1.51,1.55)) and stroke (OR 1.26 (95% CI 1.22,1.30)) whilst those with historical 
cancer had reduced odds of either event (MACCE: OR 0.88 (95% CI 0.87,0.89), stroke: OR 
0.85 (95% CI 0.83,0.87)) compared to no cancer. The odds of bleeding complications were 2-
fold higher in patients with current cancer compared to those without cancer, (OR 1.98 (95% 
CI 1.95,2.00)), with only a modest increase in odds in the historical cancer group (OR 1.04 
(95% CI 1.03,1.06)). Similar findings were observed in patients admitted between 2010 and 
2014 (Supplemental Table 4), and in the STEMI group (Supplemental Table 5) Finally, a 
propensity score matched analysis was conducted as a sensitivity analysis. (Supplemental 
Table 6). The results compared any cancer diagnosis to no cancer, and support the results seen 
in the main analysis.  
2. Four Most Prevalent Cancer Diagnoses 
The prevalence rates of the 10 most common cancer types are depicted in Supplemental 
Figure 1. In patients who were admitted with AMI, the four most common malignancies were 
prostate, breast, colon, and lung cancer. Approximately 98% of patients diagnosed with breast 
cancer were female, while diagnoses of colon and lung cancer had a broader sex distribution, 
although there were consistently less females than males across all diagnoses (ranges between 
42.2% and 41.4%). The number of patients with prostate, breast and colon cancer remain fairly 
stable, however, over time there was a much larger variability in the number of patients with 
lung cancer (from 55 people per 10 000 records up to over 68 people per 10 000 records in 
2007 and 60 per 10 000 records in 2014). 
Patients across the 4 different cancer types were less likely to be admitted with a 
primary diagnosis of STEMI and were on average older than the patients admitted with no 
cancer. (Table 3) Patients with prostate cancer had the highest median age (79 (72,85) years). 
Patient with cancer diagnosis were less likely to receive invasive treatments. Patients with lung 
cancer were the least likely to receive any treatment, with only 21% of patients receiving a PCI 
compared to 43.8% of patients with no cancer.  
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2.1 Clinical outcomes 
The incidence of in-hospital mortality, MACCE, bleeding and stroke were all higher in 
the different cancer types than patients with no cancer. (Table 4) The highest in-hospital 
mortality rates occurred in patients with lung cancer, which was nearly 3 times greater 
compared to patients with no cancer (15.7% vs 5.7%). Patients who were medically managed 
had mortality outcomes consistently worse than those observed in patients that were managed 
invasively, with in-hospital mortality rates varying between 13.3% to 19.3% compared to 
11.1% in patients that were managed medically that did not have an active cancer diagnosis. 
(Figure 4) Supplemental Figure 2 shows the crude in-hospital mortality of the 4 considered 
cancer types and whether metastases were present, with the percentage of records that received 
each of the different treatment types, medically managed, angiography, PCI or CABG. We also 
report the percentage of records with each unadjusted outcome stratified by the receipt of 
radiotherapy. (Supplemental Table 7) 
Patients with any of the four types of cancer had an increased risk of MACCE, mortality 
and stroke compare to patients with no cancer. (Table 5) The odds of MACCE and mortality 
were highest  (2-fold) in the lung cancer group compared to those without cancer (OR 2.38 
(95% CI 2.31,2.45) and OR 2.71 (95% CI 2.65,2.80), respectively), followed by colon cancer 
(OR 1.49 (95% CI 1.39,1.59 and OR 1.68 (95% CI 1.56,1.81). (Figure 5) The odds of bleeding 
were highest in the colon cancer group (OR 2.82 (95% CI 2.68,2.98), compared to those 
without cancer, followed by lung cancer (OR 2.06 (95% CI 2.00-2.12). The odds of stroke were 
only significantly raised in patients with lung cancer (OR 2.31 (95% CI 2.12,2.52) but no 
difference was observed between other cancer groups and those without cancer. Similar 
findings were observed in patients admitted between 2010 and 2014 (Supplemental Table 8), 
and in the STEMI subgroup (Supplemental Table 9). Several factors other than cancer 
diagnosis were associated with increased in-hospital mortality, including STEMI, peripheral 
vascular disease, female sex, renal failure and coagulopathies, and advanced age. 
(Supplemental Table 10).  
Mortality was higher when metastases were present for all types of cancer. 
(Supplemental Table 11) When the different cancer types are stratified into the whether or not 
metastases were present, the outcomes of patients with metastases were significantly worse 
than in patients without metastases and patients without a cancer diagnosis. In the no metastases 
group, once differences in baseline covariates were adjusted for, only patients with lung cancer 
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had an increase in the odds of in-hospital mortality, (OR 1.73 (95% CI 1.44, 2.08), Figure 5) 
compared to patients without cancer.  
Overall, the adjusted odds of adverse events (MACCE, mortality and bleeding) were 
significantly higher in patients with metastases than those without, however, there were 
exceptions according to the type of cancer and metastases status. (Supplemental Table 12) 
There was no difference in MACCE and mortality between patients with non-metastatic breast 
and prostate cancers and those without cancer (OR 0.92, 95% CI 0.82, 1.02 and OR 1.02, 95% 
CI 0.96, 1.08, respectively), and no difference in bleeding in patients with non-metastatic breast 
cancer (OR 1.07, 95% CI 0.99, 1.17). Furthermore, there was no difference in stroke between 
patients with breast and colon cancers and those without cancer regardless of metastases status.     
Discussion 
 
The present study of over 6.5 million patients is the largest to report the prevalence and 
outcomes of patients with cancer in a national cohort of AMI hospitalisations, and shows that 
close to 1 in 10 patients had either a current or historical diagnosis of cancer, with lung, breast, 
colon and prostate cancers being the four most prevalent cancers. We observe a rise in the 
prevalence of cancer in patients presenting with AMI, mainly driven by an increase in patients 
with a historical diagnosis of cancer. This could be explained by the improvement in cancer 
therapies leading to an rise in the number of cancer survivors.19 In our study patients in the 
cancer group who presented with AMI were older and had more comorbidities, consistent with 
the findings of previous studies. 10, 11, 20 We demonstrate that patients with a current diagnosis 
of cancer are less likely to receive invasive management (coronary angiography, PCI or 
CABG), compared to patients without cancer, despite invasive management being consistently 
associated with lower in-hospital mortality rates irrespective of the type of cancer diagnosis. 
We also observe a disparity in outcomes depending on the subtype of cancer and metastases 
status, with outcomes generally worse in patients with metastases. Once baseline risk profile 
was adjusted for, in the absence of metastases, lung cancer and colon cancers were associated 
a higher risk of in-hospital mortality whereas prostate and breast cancers were not. In the 
presence of metastases, all common cancer subtypes (breast, prostate, colon and lung) were at 
a higher risk of mortality, bleeding and stroke, compared to those without cancer.   
 There was considerable disparity in invasive management strategies depending on the 
presence and type of cancer in the present study. Patients with a current cancer diagnosis were 
at least 36% less likely to receive an invasive management strategy, even after adjustment for 
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other baseline differences. Amongst the most prevalent cancer groups, lung cancer patients 
were the least likely to receive coronary angiography and PCI compared to those without 
cancer. Interestingly, patients managed medically amongst all types of cancer diagnosis had 
consistently higher inpatient mortality rates compared to those patients managed by an invasive 
strategy by a factor between two to three. Whilst there may be an element of selection bias, 
where the lower risk “healthier” cancer patients are more likely to be invasively managed, our 
data provide supporting data for invasive management of such patients. To date, no randomised 
trial has evaluated the risks and benefits of conservative versus invasive strategies for treatment 
of AMI in cancer patients, who are frequently excluded from major randomized AMI trials.13 
 Abnormalities in hematologic parameters such as anaemia and thrombocytopenia and 
procoagulant states associated with certain types of cancer pose challenges for treatment. 21-23 
The presence of malignancy was shown to be an independent predictor of stent thrombosis in 
the Dutch Stent Thrombosis Registry. 24 In an observational study of STEMI patients by 
Velders et al a diagnosis of cancer in the 6 months before primary PCI was strongly associated 
with early cardiac mortality. 11 In an analysis by Tabata et al malignancy was found to be an 
independent predictor of target lesion revascularization (TLR) following PCI. They also 
reported that time since completion of cancer treatment had an impact on the rate of TLR, 
which was the most among those with a current or recent cancer history. 9 The Society of 
Coronary Angiography and Interventions (SCAI) has put forth an expert consensus statement 
with emphasis on special considerations regarding coronary angiography and interventions in 
cancer patients.12 It includes a recommended revascularization approach that takes into account 
the platelet count, TIMI risk score and the early involvement of a cardio-oncology team.  
Our analysis also reveals that patients with AMI and current cancer were associated 
with at least 50% increased risk of MACCE, bleeding complications and in-hospital mortality 
as compared to those without no cancer, whereas patients with historical cancer were at no 
increased risk of adverse outcomes other than bleeding. Even when data was limited to the last 
4 years of our study (2010-2014) for a more contemporary assessment of risk, similar findings 
were recorded. Although these findings are consistent with some previous studies, the majority 
of published outcomes data in this population are limited to PCI registries 8, 10, 11, 25, 26 with 
obvious exclusion of patients who were medically treated. Furthermore, prior studies 
considered cancer as a single condition, despite prognostic differences between cancer types 
and stages, and choice of revascularization (or lack thereof), as demonstrated in the present 
study. Subgroup analysis of the BleeMACS registry revealed that at one-year follow-up, 
patients with cancer more often experienced the composite endpoint of death and re-infarction 
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(15.2% vs. 5.3%, P<0.001) and bleeding (6.5% vs. 3%, P<0.001) as compared to those without 
cancer. 10 In a retrospective analysis from Israel, cancer survivors (mean cancer diagnosis-to-
PCI interval was 3.6±3.4 years) had a 40% increased risk of a composite end point of death, 
nonfatal MI, target vessel revascularization, and coronary bypass surgery, over a mean follow-
up period of 6.4±5.9 years. 25 In contrast, analysis of outcomes following PCI in cancer patients 
from the Duke 8 and Mayo 26 registries have, reported disparate findings. In the Duke study, 
the different subgroups of patients that were studied included ‘pre-PCI cancer’ (any cancer 
treatment before PCI), ‘post-PCI cancer’ (patients who received cancer treatment after the 
index PCI) and ‘recent cancer’ (cancer treatment within 1 year pre-PCI). In this database the 
majority of patients received PCI for acute coronary syndrome. The adjusted risk of long-term 
cardiovascular mortality was not significantly different in pre-PCI cancer versus non-cancer 
patients. However, for patients with post-PCI cancer, some of whom may have had occult 
cancer at the time of PCI, adjusted risk of cardiovascular mortality was significantly greater 
than for controls. 8 Analysis of data from the Mayo Clinic PCI registry, which included STEMI 
patients, revealed that patients with cancer had a higher in-hospital non-cardiac mortality but 
similar cardiac mortality as matched controls. Even at 6.2 years of median follow up the higher 
mortality seen in the cancer group was due to non-cardiac causes. 26.  
An important aspect of our study is that there is considerable variation in clinical 
outcomes following AMI depending on the type of cancer and the presence of metastases. Most 
previous studies 8, 10, 11, 25, 26, which have evaluated outcomes of AMI in cancer patients, lack 
granularity in terms of the type of cancer or presence of metastases. Given the different types 
of cancer and variations in their therapy and prognosis, this raises concerns about using a single 
pooled diagnosis of cancer for analysis. We show that patients with metastases were generally 
associated with worse adverse outcomes after AMI, except for stroke in patients with breast 
and colon cancer that was insignificant regardless of metastasis status. Patients with a diagnosis 
of lung cancer had the highest incidence of mortality, MACCE and stroke, which was further 
increased in the presence of metastases. A previous study which included only STEMI patients 
from the National Inpatient Sample database revealed that in-hospital mortality was 57.1% in 
patients with lung cancer, which was more than double that of the group without cancer 
(25.7%).20 In our study the odds of having a bleeding complication were close to 3-fold higher 
in patients with colon cancer, and we and others have shown that the presence of colon cancer 
to be an independent predictor of bleeding following PCI.27, 28 A 10-year observation study of 
49,515 patients with metastatic cancer and ACS suggested that even PCI did not provide 
mortality benefits compared to conservative medical therapy in this cohort. 29  
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The strength of our study lies in the large sample size, which is representative of a real-
world population. Ours is the first study to present a comparison of data regarding co-
morbidities, variations in treatment and clinical outcomes based on the type of cancer, which 
is lacking in most previous studies. Most of the previous studies relating to AMI in cancer 
patients are derived from PCI registries 8, 10, 11, 25, 26 thereby omitting a significant subgroup of 
patients who were medically managed. We acknowledge several limitations of our study, 
which are inherent to the database. The NIS does not capture data regarding the timing of 
cancer diagnosis, status of cancer therapy with relation to the AMI, which may in fact be a 
major prognostic factor as has been shown previously, 11 or cause of death, and lacks data 
regarding long term outcomes thereby limiting us to just in-hospital events. Furthermore, we 
were unable to stratify bleeding based on standardized definitions used in cardiovascular trials 
(major vs. minor).30 The NIS also does not capture information on antithrombotic regimes, 
which may contribute to outcomes, particularly if patients with cancer are prescribed less 
potent anti-platelet agents or dual antiplatelet therapy due to concerns around major bleeding 
complications, or chemotherapy regimens. The latter may predispose to complications such as 
re-infarction or major bleeding, and absence of information on whether chemotherapy is 
ongoing or completed can represent a source of bias when evaluating the true outcomes in the 
oncologic setting. Furthermore, the NIS also does not capture haematological information such 
as anaemia or thrombocytopenia that will serve to impact both treatment decisions and clinical 
outcomes (e.g. bleeding complications). Finally, as with most administrative databases, coding 
errors and underreporting of secondary diagnoses are always a potential source of bias.  
Conclusion 
In conclusion patients with current or historical diagnosis of cancer who present with 
AMI have more comorbidities as compared to those without cancer. The majority of these 
patients are treated conservatively without PCI and outcomes such as in-hospital mortality and 
MACCE are greater. Furthermore, there is considerable variation in clinical outcomes noted 
among different types of cancer with lung cancer being associated with worse mortality 
outcomes with the risk of bleeding significantly higher in patients with a diagnosis of colon 
cancer. Additionally, the presence of metastasis is associated with worse clinical outcomes 
irrespective of the type of cancer. With an abject lack of data from randomized trials, the 
clinician is often faced with numerous clinical and therapeutic conundrums when treating 
cancer patients who present with AMI. These patients should be approached from a 
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multidisciplinary standpoint involving cardiology and oncology positioning the current AMI 
in the context of the expected prognosis and tailoring the treatment accordingly.  
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Figure Legends  
Figure 1. Flow diagram of study population selection 
Caption: AMI: acute myocardial infarction 
Figure 2: Changes in number of records with either a current of historical cancer diagnosis over 
time.  
Figure 3: Distribution of treatments among current, historical and no cancer diagnoses 
Caption: CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention 
Figure 4: Crude mortality for patients with a current diagnosis of the 4 considered cancers 
stratified by treatment received 
Caption: *No CABG cases; CABG: coronary artery bypass grafting; PCI: percutaneous coronary 
intervention 
Figure 5: Adjusted odds ratios for adverse events according to cancer type and presence of 
metastases.  
Caption: MACCE: composite of all-cause mortality, cardiac complications and stroke 
 
